Recce Pharmaceuticals (ASX:RCE) has received patent acceptance in China for its synthetic anti-infectives Recce 327 and Recce 529, with protection valid until 2041, according to a Monday filing with the Australian bourse.
The patent covers the manufacturing processes of the infectives and their use across a range of infections, including diabetic foot infections, pneumonia, and COVID-19, the filing said.
It also includes the administration of the infectives by various delivery methods, the filing added.
Shares of the company rose 2% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。